29-01-2025 | Breast Cancer | Breast Oncology
Ongoing Symptoms and Concerns Experienced by Low-Risk Breast Cancer Survivors Following Active Treatment
Authors:
Jessica R. Schumacher, PhD, Jennifer L. Tucholka, PA-C, BS, Catherine R. Breuer, MS, Grace H. McKinney, MMSc, Courtney Maxcy, MPH, Trista J. Stankowski-Drengler, MD, MS, Nicholas A. Marka, MS, Bret M. Hanlon, PhD, Kristine L. Kwekkeboom, PhD, RN, FAAN,, Amye J. Tevaarwerk, MD, James E. Haine, MD, Heather B. Neuman, MD, MS
Published in:
Annals of Surgical Oncology
Login to get access
Abstract
Introduction
Little is known about the symptom burden of breast cancer survivors with early-stage disease. Many studies have focused on symptoms of patients who are undergoing or recently completed systemic therapy. However, with the increased use of Oncotype DX, the proportion of early-stage hormone receptor-positive patients who undergo chemotherapy has declined, making existing studies of the symptom experience less useful for these patients.
Objective
The aim of this study was to assess symptom burden for early-stage breast cancer survivors.
Methods
Eligible survivors had stage I–II, estrogen receptor (ER)- or progesterone receptor (PR)-positive and HER2neu-negative breast cancer, did not receive chemotherapy, were 6 months–5 years post-diagnosis, and were cancer-free. Survivors were enrolled at the University of Wisconsin Breast Center follow-up visits and were emailed a link to a patient-reported outcomes (PRO) survey. Survey domains were informed by American Cancer Society/American Society of Clinical Oncology (ACS/ASCO) survivorship guidelines and survivor/provider stakeholders. The prevalence of clinically significant symptoms are reported.
Results
Overall, 98 patients participated. On average, participants were 61.3 years of age (standard deviation [SD] 11.5) and 2.5 years post-diagnosis (SD 1.2); 71.3% underwent breast-conserving surgery. The average item-level missingness rate was low (2.0%). Most survivors (86.2%) experienced symptoms (38.8% reporting one to two symptoms; 47.9% reporting more than three symptoms).
Conclusions
Early-stage breast cancer survivors report a high symptom burden. Given nearly 50% of survivors report more than three symptoms, many topics may not be discussed or addressed during time-limited follow-up visits. Some symptoms, such as sexual health, may be less feasible to address in-clinic given their complex/sensitive nature. Use of PROs allows for a comprehensive evaluation and identification of unrecognized needs, representing an opportunity to improve survivorship care.